Atopic Dermatitis Treatment Market, By Product (Calcineurin Inhibitors, Corticosteroids, Biologic Therapy, Immunosuppressants, and Others), By Route of Administration (Oral, Topical, Injectable), By End-Users (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Atopic Dermatitis Treatment Market was valued at US$ 6 Billion in 2024 and is projected to grow at a CAGR of 5.30% to reach US$ 10 Billion by 2034.

Atopic Dermatitis is also called as eczema, a chronic disease that causes redness, inflammation and irritation of skin. Emollients moisturizer are common treatment for atopic dermatitis that are used every day by an infected individual. Various product such as Calcineurin Inhibitors, Corticosteroids, Biologic Therapy, Immunosuppressants, and Others are used in treatment of Atopic Dermatitis.

Growing Prevalence of Eczema to fuel market growth

Growing prevalence of eczema or atopic dermatitis have become major contribution in target market growth. Environmental exposure, genetics and changing lifestyle factors have contributed in development & progression of eczema. For instance, according to National Eczema Association, around 31.6 million Americans area affected by an eczema an incredibly inflammatory skin condition which begins in first year of life.

Further, in 2021, according to CDC (Centers for Disease Control and Prevention), in United States, the percentage of adults diagnosed with eczema varied by age, sex, race and Hispanic origin. The percentage of eczema was higher in woman about 8.9% as compared to men about 5.7%.

Restrains:

However, expensive treatment of eczema has hampered the demand for Atopic Dermatitis Treatment Market growth.

Atopic Dermatitis Treatment Market Segmentation:

Atopic Dermatitis Treatment Market is segmented based on Product, Route of Administration, End-Users and Region.

Product Insight

On the basis of Product, Atopic Dermatitis Treatment Market is segmented into Calcineurin Inhibitors, Corticosteroids, Biologic Therapy, Immunosuppressants, and Others.

Route of Administration Insight

On the basis of Route of Administration, Atopic Dermatitis Treatment Market is segmented into Oral, Topical, Injectable.

End-Users Insights

On the basis of End-Users, Atopic Dermatitis Treatment Market is segmented into Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others.

Atopic Dermatitis Treatment Market Regional Insights:

On region the Atopic Dermatitis Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America market is estimated to witness a significantly high revenue share over the forecast period due to rising prevalence of eczema, continuous research & development activities and well established healthcare infrastructure.

Asia Pacific market is estimated to witness a fastest revenue share over the forecast period due to growing population, rising incidence of atopic dermatitis and growing awareness among consumers for better treatment.

Recent Development:

             The New Launched Product News,

• In May 2023, Eli Lilly uneviled new data from its atopic dermatitis new therapy Phase III trials. The new therapy trial shows about 58% to 73% of patients who received lebrikizumab has experienced cleared face dermatitis in 16 weeks after medication.
• In January 2022, ‘CIBINQO’ (abrocitinib) an oral treatment developed by Pfizer Inc., for adults with moderate-to-severe atopic dermatitis condition has been approved by U.S. FDA (Food and Drug Administration). The new launched approved drug is recommended at doses of 100 mg and 200 mg.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034

The key players operating the Atopic Dermatitis Treatment Market includes, Novartis, Sanofi SA, Bayer AG, Galderma SA, Bristol-Myers Squibb, Allergan Plc., Astellas Pharma Inc., Regeneron Pharmaceuticals, Anacor Pharmaceuticals, Meda Pharmaceuticals and Others.

• Novartis
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Sanofi SA
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Bayer AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Galderma SA
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bristol-Myers Squibb
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Allergan Plc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Astellas Pharma Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Regeneron Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Anacor Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Meda Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

1. The Last Word
   • Future Impact
   • About Us
   • Contact